Medicare Advantage Will Officially Exclude These Items in 2026

CMS will impose new 2026 restrictions on Special Supplemental Benefits for the Chronically Ill (SSBCI), a Medicare Advantage expansion created under the Bipartisan Budget Act of 2018, limiting coverage for items such as alcohol, tobacco and cannabis products, life and hospital indemnity insurance, funeral expenses, strictly cosmetic procedures, broad non-health membership programs and unspecified “non-healthy” foods. Plans must propose allowed SSBCI benefits in their annual bids and are subject to CMS review, meaning actual offerings will vary by insurer and could raise out-of-pocket costs for some enrollees while narrowing ancillary benefit exposure for plans.

Analysis

Market structure: CMS’s 2026 SSBCI carve-outs remove many high-friction, nonclinical perks (alcohol, funeral services, “non-healthy” groceries), which favors insurers with strong clinical-management capabilities (UNH, ELV, CVS) and squeezes boutique MA differentiators that relied on consumer goods. Net financial impact is likely modest at plan level — order-of-magnitude savings per enrollee of tens to low hundreds of dollars annually — but it changes marketing competitiveness and could reduce enrollment elasticity for fringe-benefits-focused plans (smaller MA players, some regional carriers).

Risk assessment: Immediate market moves should be muted (days) because the rule is already public; short-term (weeks–months) risk centers on plan bid filings and marketing shifts ahead of AEP Oct–Dec 2025; long-term (2026 onward) risk is enrollment migration and margin reallocation. Tail risks include stricter CMS reinterpretation or litigation that broadens restrictions (high impact on MA mix) and political pushback that forces rollback; hidden dependencies include plan decisions on food-benefit design which can shift spend into clinical home-delivery or pharmacy channels.

Trade implications: Favor diversified insurers and service integrators: long UNH and ELV exposure, underweight or hedge Humana (HUM) and smaller MA-focused names; implement size limits (2–3% portfolio longs, 0.5–1% shorts) and use options to cap downside. Monitor CMS communications and plan bid releases through mid-2025 and AEP enrollment flows in Q4 2025 as execution catalysts; if enrollment declines >2–3% for a given carrier versus peers, widen shorts.

Contrarian angles: The market may underappreciate reallocation upside — plans will likely redeploy savings into evidence-based chronic-care (home health, RPM, nutrition counseling), boosting vendors in those channels and improving medical-loss ratios (20–100 bps potential). Conversely, if plans monetize by raising premiums to offset perceived benefit loss, expect regulatory scrutiny and potential reversals — that policy risk is the chief non-linear threat.

Key Decisions for Investors

• Establish a 2–3% long position in UnitedHealth Group (UNH) over the next 30–90 days; rationale: diversified Optum revenue and clinical management should capture benefit reallocation. Trim or exit if UNH rises >10% or reports AEP enrollment miss >1% versus consensus.
• Initiate a 1–2% long in Elevance Health (ELV) and a 1% long in CVS Health (CVS) to play PBM/retail capture of redirected SSBCI spend; re-evaluate after plan-bid disclosures (expected rolling through mid-2025).
• Open a 0.5–1% notional protective position: buy 3–6 month HUM (Humana) puts ~5%–10% OTM as insurance against enrollment erosion; if HUM share drops >15% trim puts and convert to small outright short.
• Run a pair trade: long UNH (1.5%) / short HUM (1%) to express relative resilience; close pair if UNH/HUM relative performance diverges by >10% or if CMS issues clarifying guidance that materially favors smaller MA plans.
• Monitor CMS plan-bid filings and AEP enrollment reports through Oct–Dec 2025; if a carrier’s MA membership declines by >2–3% QoQ or announces >$25 PMPY benefit cut, increase short exposure to that ticker by up to 1–2%.